Immunotoxins for targeted cancer therapy

AAPS Journal

Volumn 8, Issue 3, 2006, Pages

  Kreitman, Robert J ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

CD22; CD25; Diphtheria; Interleukin; Monoclonal antibody; Pseudomonas

Indexed keywords

ALEMTUZUMAB; ANTINEOPLASTIC AGENT; AURISTATIN PE; BACTERIAL TOXIN; BEXAROTENE; CALICHEAMICIN; CARBOHYDRATE ANTIGEN; CD19 ANTIGEN; CD22 ANTIGEN; CD30 ANTIGEN; CYCLOSPORIN; DENILEUKIN DIFTITOX; DENILEUKIN DIFTITOX GRANULOCYTE MACROPHAGE COLONY STIMULA FACTOR FUSION PROTEIN; DIPHTHERIA TOXIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEMTUZUMAB OZOGAMICIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR; IMMUNOTOXIN; IMMUNOTOXIN LMB2; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 4 PSEUDOMONAS EXOTOXIN FUSION PROTEIN; MONOCLONAL ANTIBODY; PLANT TOXIN; PSEUDOMONAS EXOTOXIN; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RITUXIMAB; TRANSFERRIN RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BINDING AFFINITY; BINDING SITE; BODY WEIGHT DISORDER; BONE MARROW TOXICITY; BONE PAIN; CANCER REGRESSION; CANCER THERAPY; CLINICAL TRIAL; CUTANEOUS T CELL LYMPHOMA; CYTOSOL; DERIVATIZATION; DOSE RESPONSE; DRUG APPROVAL; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; DRUG POTENCY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG REEXPOSURE; DRUG SAFETY; DRUG TARGETING; GRAFT VERSUS HOST REACTION; HAIRY CELL LEUKEMIA; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; HYPOALBUMINEMIA; HYPOTENSION; IMMUNOGENICITY; LIGAND BINDING; LIVER TOXICITY; NEUROTOXICITY; NONHODGKIN LYMPHOMA; NONHUMAN; PROTEIN DOMAIN; PROTEIN SYNTHESIS INHIBITION; PROTEIN TARGETING; RADIOIMMUNOTHERAPY; REVIEW; SOLID TUMOR; TREATMENT OUTCOME; TREATMENT RESPONSE; WEIGHT GAIN;

ANTIGENS, CD22; ANTINEOPLASTIC AGENTS; BACTERIAL TOXINS; CLINICAL TRIALS; DIPHTHERIA TOXIN; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOGLOBULIN FRAGMENTS; IMMUNOTOXINS; INTERLEUKIN-2; LEUKEMIA, HAIRY CELL; RECOMBINANT FUSION PROTEINS;

EID: 33748309412     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/aapsj080363     Document Type: Review

References (290)

1. Moolten FL, Cooperband SR. Selective destruction of target cells by diphtheria toxin conjugated to antibody directed against antigens on the cells. Science. 1970;169:68-70.
2. Krolick KA, Villemez C, Isakson P, Uhr JW, Vitetta ES. Selective killing of normal or neoplastic B cells by antibodies coupled to the A chain of ricin. Proc Natl Acad Sci USA. 1980;77: 5419-5423.
3. Cawley DB, Herschman HR, Gilliland DG, Collier RJ. Epidermal growth factor-toxin A chain conjugates: EGF-ricin A is a potent toxin while EGF-diphtheria fragment A is nontoxic. Cell. 1980;22:563-570.
4. Akhtar S, Maghfoor I. Rituximab plus CHOP for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:1830-1831.
5. Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood. 2002;99: 3554-3561.
6. Cheson B. Bexxar (Corixa/GlaxoSmithKline). Curr Opin Investig Drugs. 2002;3:165-170.
7. Nabhan C, Tallman MS. Early phase I/II trials with gemtuzumab ozogamicin (Mylotarg(R)) in acute myeloid leukemia. Clin Lymphoma. 2002;2:S19-S23.
8. Francisco JA, Cerveny CG, Meyer DL, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003;102:1458-1465.
9. Naito K, Takeshita A, Shigeno K, et al. Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (Gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines. Leukemia. 2000;14:1436-1443.
10. Hursey M, Newton DL, Hansen HJ, Ruby D, Goldenberg DM, Rybak SM. Specifically targeting the CD22 receptor of human B-cell lymphomas with RNA damaging agents: a new generation of therapeutics. Leuk Lymphoma. 2002;43:953-959.
11. Yamaizumi M, Mekada E, Uchida T, Okada Y. One molecule of diphtheria toxin fragment A introduced into a cell can kill the cell. Cell. 1978;15:245-250.
12. Eiklid K, Olsnes S, Pihl A. Entry of lethal doses of abrin, ricin and modeccin into the cytosol of HeLa cells. Exp Cell Res. 1980;126:321-326.
13. Carroll SF, Collier RJ. Active site of Pseudomonas aeruginosa exotoxin A. Glutamic acid 553 is photolabeled by NAD and shows functional homology with glutamic acid 148 of diphtheria toxin. J Biol Chem. 1987;262:8707-8711.
14. Bolognesi A, Polito L, Tazzari PL, et al. in vitro anti-tumour activity of anti-CD80 and anti-CD86 immunotoxins containing type 1 ribosome-inactivating proteins. Br J Haematol. 2000;110:351-361.
15. Endo Y, Mitsui K, Motizuki M, Tsurugi K. The mechanism of action of ricin and related toxic lectins on eukaryotic ribosomes. J Biol Chem. 1987;262:5908-5912.
16. Bolognesi A, Tazzari PL, Olivieri F, Polito L, Falini B, Stirpe F. Induction of apoptosis by ribosome-inactivating proteins and related immunotoxins. Int J Cancer. 1996;68:349-355.
17. Hughes JN, Lindsay CD, Griffiths GD. Morphology of ricin and abrin exposed endothelial cells is consistent with apoptotic cell death. Hum Exp Toxicol. 1996;15:443-451.
18. Bergamaschi G, Perfetti V, Tonon L, et al. Saporin, a ribosome-inactivating protein used to prepare immunotoxins, induces cell death via apoptosis. Br J Haematol. 1996;93:789-794.
19. Wesche J, Rapak A, Olsnes S. Dependence of ricin toxicity on translocation of the toxin A-chain from the endoplasmic reticulum to the cytosol. J Biol Chem. 1999;274:34443-34449.
20. Tagge E, Harris B, Burbage C, et al. Synthesis of green fluorescent protein-ricin and monitoring of its intracellular trafficking. Bioconjug Chem. 1997;8:743-750.
21. Fulton RJ, Uhr JW, Vitetta ES. In vivo therapy of the BCL1 tumor: effect of immunotoxin valency and deglycosylation of the ricin A chain. Cancer Res. 1988;48:2626-2631.
22. Bourrie BJ, Casellas P, Blythman HE, Jansen FK. Study of the plasma clearance of antibody-ricin-A-chain immunotoxins. Evidence for specific recognition sites on the A chain that mediate rapid clearance of the immunotoxin. Eur J Biochem. 1986;155:1-10.
23. Blakey DC, Watson GJ, Knowles PP, Thorpe PE. Effect of chemical deglycosylation of ricin A chain on the in vivo fate and cytotoxic activity of an immunotoxin composed of ricin A chain and anti-Thy 1.1 antibody. Cancer Res. 1987;47:947-952.
24. Thorpe PE, Wallace PM, Knowles PP, et al. Improved antitumor effects of immunotoxins prepared with deglycosylated ricin A-chain and hindered disulfide linkages. Cancer Res. 1988;48: 6396-6403.
25. Ramakrishnan S, Bjorn MJ, Houston LL. Recombinant ricin A chain conjugated to monoclonal antibodies: improved tumor cell inhibition in the presence of lysosomotropic compounds. Cancer Res. 1989;49:613-617.
26. Lambert JM, McIntyre G, Gauthier MN, et al. The galactose-binding sites of the cytotoxic lectin ricin can be chemically blocked in high yield with reactive ligands prepared by chemical modification of glycopeptides containing triantennary N-linked oligosaccharides. Biochemistry. 1991;30:3234-3247.
27. Mohanraj D, Ramakrishnan S. Cytotoxic effects of ricin without an interchain disulfide bond: genetic modification and chemical crosslinking studies. Biochim Biophys Acta. 1995;1243:399-406.
28. Kreitman RJ, Chaudhary VK, Siegall CB, FitzGerald DJ, Pastan I. Rational design of a chimeric toxin: an intramolecular location for the insertion of transforming growth factor a within Pseudomonas exotoxin as a targeting ligand. Bioconjug Chem. 1992;3:58-62.
29. Cook JP, Savage PM, Lord JM, Roberts LM. Biologically active interleukin-2-ricin A chain fusion proteins may require intracellular proteolytic cleavage to exhibit a cytotoxic effect. Bioconjug Chem. 1993;4:440-447.
30. Dore JM, Gras E, Wijdenes J. Expression and activity of a recombinant chimeric protein composed of pokeweed antiviral protein and of human interleukin-2. FEBS Lett. 1997;402:50-52.
31. Francisco JA, Gawlak SL, Siegall CB. Construction, expression, and characterization of BD1-G28-5 sFv, a single-chain anti-CD40 immunotoxin containing the ribosome-inactivating protein bryodin 1. J Biol Chem. 1997;272:24165-24169.
32. Fabbrini MS, Carpani D, Bello-Rivero I, Soria MR. The amino-terminal fragment of human urokinase directs a recombinant chimeric toxin to target cells: internalization is toxin mediated. FASEB J. 1997;11:1169-1176.
33. Tetzke TA, Caton MC, Maher PA, Parandoosh Z. Effect of fibroblast growth factor saporin mitotoxins on human bladder cell lines. Clin Exp Metastasis. 1997;15:620-629.
34. Kreitman RJ. Getting plant toxins to fuse. Leuk Res. 1997;21:997-999.
35. Phan LD, Perentesis JP, Bodley JW. Saccharomyces cerevisiae elongation factor 2. Mutagenesis of the histidine precursor of diphthamide yields a functional protein that is resistant to diphtheria toxin. J Biol Chem. 1993;268:8665-8668.
36. Hwang J, FitzGerald DJ, Adhya S, Pastan I. Functional domains of Pseudomonas exotoxin identified by deletion analysis of the gene expressed in E. coli. Cell. 1987;48:129-136.
37. Allured VS, Collier RJ, Carroll SF, McKay DB. Structure of exotoxin A of Pseudomonas aeruginosa at 3.0 Angstrom resolution. Proc Natl Acad Sci USA. 1986;83:1320-1324.
38. 280 generates the enzymatically active fragment which translocates to the cytosol. J Biol Chem. 1992;267:25396-25401.
39. Uchida T, Jr, Pappenheimer AM, Jr, Harper AA. Reconstitution of diphtheria toxin from two nontoxic cross-reacting mutant proteins. Science. 1972;175:901-903.
40. r ∼ 6000 region of the toxin. J Biol Chem. 1990;265:7331-7337.
41. Kaul P, Silverman J, Shen WH, et al. Roles of Glu 349 and Asp 352 in membrane insertion and translocation by diphtheria toxin. Protein Sci. 1996;5:687-692.
42. Li M, Dyda F, Benhar I, Pastan I, Davies DR. Crystal structure of the catalytic domain of Pseudomonas exotoxin A complexed with a nicotinamide adenine dinucleotide analog: implications for the activation process and for ADP ribosylation. Proc Natl Acad Sci USA. 1996;93:6902-6906.
43. Hessler JL, Kreitman RJ. An early step in Pseudomonas exotoxin action is removal of the terminal lysine residue, which allows binding to the KDEL receptor. Biochemistry. 1997;36:14577-14582.
44. Kounnas MZ, Morris RE, Thompson MR, FitzGerald DJ, Strickland DK, Saelinger CB. The α2-macroglobulin receptor/low density lipoprotein receptor-related-protein binds and internalizes Pseudomonas exotoxin A. J Biol Chem. 1992;267:12420-12423.
45. Chiron W, Fryling CM, FitzGerald DJ. Cleavage of Pseudomonas exotoxin and diphtheria toxin by a furin-like enzyme prepared from beef liver. J Biol Chem. 1994;269: 18167-18176.
46. McKee ML, FitzGerald DJ. Reduction of furin-nicked Pseudomonas exotoxin A: an unfolding story. Biochemistry. 1999;38:16507-16513.
47. Chaudhary VK, Jinno Y, FitzGerald D, Pastan I. Pseudomonas exotoxin contains a specific sequence at the carboxyl terminus that is required for cytotoxicity. Proc Natl Acad Sci USA. 1990;87:308-312.
48. Kreitman RJ, Pastan I. Importance of the glutamate residue of KDEL in increasing the cytotoxicity of Pseudomonas exotoxin derivatives and for increased binding to the KDEL receptor. Biochem J. 1995;307:29-37.
49. Theuer C, Kasturi S, Pastan I. Domain II of Pseudomonas exotoxin A arrests the transfer of translocating nascent chains into mammalian microsomes. Biochemistry. 1994;33:5894-5900.
50. Theuer CP, Buchner J, FitzGerald D, Pastan I. The N-terminal region of the 37-kDa translocated fragment of Pseudomonas exotoxin A aborts translocation by promoting its own export after microsomal membrane insertion. Proc Natl Acad Sci USA. 1993;90: 7774-7778.
51. Keppler-Hafkemeyer A, Kreitman RJ, Pastan I. Apoptosis induced by immunotoxins used in the treatment of hematologic malignancies. Int J Cancer. 2000;87:86-94.
52. Brinkmann U, Brinkmann E, Gallo M, Pastan I. Cloning and characterization of a cellular apoptosis susceptibility gene, the human homologue to the yeast chromosome segregation gene CSE1. Proc Natl Acad Sci USA. 1995;92:10427-10431.
53. Choe S, Bennett MJ, Fujii G, et al. The crystal structure of diphtheria toxin. Nature. 1992;357:216-222.
54. Bell CE, Eisenberg D. Crystal structure of diphtheria toxin bound to nicotinamide adenine dinucleotide. Biochemistry. 1996;35: 1137-1149.
55. 194. J Biol Chem. 1990;265:20673-20677.
56. D'Silva PR, Lala AK. Unfolding of diphtheria toxin: identification of hydrophobic sites exposed on lowering of pH by photolabeling. J Biol Chem. 1998;273:16216-16222.
57. Lemichez; E, Bomsel M, Devilliers G, et al. Membrane translocation of diphtheria toxin fragment A exploits early to late endosome trafficking machinery. Mol Microbiol. 1997;23:445-457.
58. Wilson BA, Blanke SR, Reich KA, Collier RJ. Active-site mutations of diphtheria toxin. Tryptophan 50 is a major determinant of NAD affinity. J Biol Chem. 1994;269:23296-23301.
59. Bennett MJ, Eisenberg D. Refined structure of monomeric diphtheria toxin at 2.3 A resolution. Protein Sci. 1994;3:1464-1475.
60. Greenfield L, Johnson VG, Youle RJ. Mutations in diphtheria toxin separate binding from entry and amplify immunotoxin selectivity. Science. 1987;238:536-539.
61. Kondo T, FitzGerald D, Chaudhary VK, Adhya S, Pastan I. Activity of immunotoxins constructed with modified Pseudomonas exotoxin A lacking the cell recognition domain. J Biol Chem. 1988;263:9470-9475.
62. Williams DP, Parker K, Bacha P, et al. Diphtheria toxin receptor binding domain substitution with interleukin-2: genetic construction and properties of a diphtheria toxin-related interleukin-2 fusion protein. Protein Eng. 1987;1:493-498.
63. Siegall CB, Chaudhary VK, FitzGerald DJ, Pastan I. Functional analysis of domains II, Ib, and III of Pseudomonas exotoxin. J Biol Chem. 1989;264:14256-14261.
64. Kreitman RJ, Batra JK, Seetharam S, Chaudhary VK, FitzGerald DJ, Pastan I. Single-chain immunotoxin fusions between anti-Tac and Pseudomonas exotoxin: relative importance of the two toxin disulfide bonds. Bioconjug Chem. 1993;4:112-120.
65. 486-IL-2). Fragment B sequences required for the delivery of fragment A to the cytosol of target cells. J Biol Chem. 1990;265:11885-11889.
66. Chaudhary VK, FitzGerald DJ, Pastan I. A proper amino terminus of diphtheria toxin is important for cytotoxicity. Biochem Biophys Res Commun. 1991;180:545-551.
67. Seetharam S, Chaudhary VK, FitzGerald D, Pastan I. Increased cytotoxic activity of Pseudomonas exotoxin and two chimeric toxins ending in KDEL. J Biol Chem. 1991;266:17376-17381.
68. Theuer CP, Kreitman RJ, FitzGerald DJ, Pastan I. Immunotoxins made with a recombinant form of Pseudomonas exotoxin A that do not require proteolysis for activity. Cancer Res. 1993;53:340-347.
69. van Oosterhout YV, van Ernst JL, Bakker HH, et al. Production of anti-CD3 and anti-CD7 ricin A-immunotoxins for a clinical pilot study. Int J Pharm. 2001;221:175-186.
70. Pai LH, Wittes R, Setser A, Willingham MC, Pastan I. Treatment of advanced solid tumors with immunotoxin LMB-1: an antibody linked to Pseudomonas exotoxin. Nat Med. 1996;2:350-353.
71. 4E, a recombinant fusion of interleukin 6 with Pseudomonas exotoxin. Bioconjug Chem. 1993;4:581-585.
72. Kreitman RJ, Pastan I. Making fusion toxins to target leukemia and lymphoma. In: Francis GE, Delgado C, eds. Drug Targeting: Strategies, Principles, and Applications. Totowa, NJ: Humana Press Inc; 2000:215-227. Methods in Molecular Medicine; vol 25.
73. Buchner J, Pastan I, Brinkmann U. A method for increasing the yield of properly folded recombinant fusion proteins: single-chain immunotoxins from renaturation of bacterial inclusion bodies. Anal Biochem. 1992;205:263-270.
74. Shao Y, Warman BE, Perentesis JP. Recombinant fusion toxins directed against the human granulocyte-macrophage colony stimulating factor (GM-CSF) receptor. Methods Mol Biol. 2001;166:31-53.
75. Choo AB, Dunn RD, Broady KW, Raison RL. Soluble expression of a functional recombinant cytolytic immunotoxin in insect cells. Protein Expr Purif. 2002;24:338-347.
76. Woo JH, Liu YY, Stavrou S, Neville DM. Increasing secretion of a bivalent anti-T-cell immunotoxin by Pichia pastoris. Appl Environ Microbiol. 2004;70:3370-3376.
77. Van Horssen PJ, Preijers FW, Van Oosterhout YV, De Witte TD. Highly potent CD22-recombinant ricin A results in complete cure of disseminated malignant B-cell xenografts in SCID mice but fails to cure solid xenografts in nude mice. Int J Cancer. 1996;68:378-383.
78. Engert A, Diehl V, Schnell R, et al. A phase-I study of an anti-CD25 ricin A-chain immunotoxin (RFT5-SMPT-dgA) in patients with refractory Hodgkin's lymphoma. Blood. 1997;89:403-410.
79. Schnell R, Vitetta E, Schindler J, et al. Treatment of refractory Hodgkin's lymphoma patients with an anfi-CD25 ricin A-chain immunotoxin. Leukemia. 2000;14:129-135.
80. Amlot PL, Stone MJ, Cunningham D. et al. A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy. Blood. 1993;82:2624-2633.
81. Sausville EA, Headlee D, Stetler-Stevenson M, et al. Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: a phase I study. Blood 1995;85:3457-3465.
82. Vitetta ES, Stone M, Amlot P, et al. Phase I immunotoxin trial in patients with B-cell lymphoma. Cancer Res. 1991;51:4052-4058.
83. Stone MJ, Sausville EA, Fay JW, et al. A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma. Blood. 1996;88:1188-1197.
84. Frankel AE, Laver JH, Willingham MC, Burns LJ, Kersey JH, Vallera DA. Therapy of patients with T-cell lymphomas and leukemias using an anti-CD7 monoclonal antibody-ricin A chain immunotoxin. Leuk Lymphoma. 1997;26:287-298.
85. Schnell R, Staak O, Borchmann P, et al. A Phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4.dgA) in patients with refractory CD30+ Hodgkin's and non-Hodgkin's lymphoma. Clin Cancer Res. 2002;8:1779-1786.
86. Laske DW, Youle RJ, Oldfield EH. Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nat Med. 1997;3:1362-1368.
87. Uckun F. Immunotoxins for the treatment of leukaemia. Br J Haematol. 1993;85:435-438.
88. Multani PS, O'Day S, Nadler LM, Grossbard ML. Phase II clinical trial of bolus infusion anti-B4 blocked ricin immunoconjugate in patients with relapsed B-cell non-Hodgkin's lymphoma. Clin Cancer Res. 1998;4:2599-2604.
89. Grossbard ML, Niedzwiecki D, Nadler LM, et al. Anti-B4-blocked ricin (Anti-B4bR) adjuvant therapy post-autologous bone marrow transplant (ABMT) (CALGB 9254): a phase III intergroup study. Proc Am Soc Clin Oncol. 1998;17:3a.
90. O'Toole JE, Esseltine D, Lynch TJ, Lambert JM, Grossbard ML. Clinical trials with blocked ricin immunotoxins. Curr Top Microbiol Immunol. 1998;234:35-56.
91. Winkler U, Barth S, Schnell R, Diehl V, Engert A. The emerging role of immunotoxins in leukemia and lymphoma. Ann Oncol. 1997;8:139-146.
92. Laske DW, Muraszko KM, Oldfield EH, et al. Intraventricular immunotoxin therapy for leptomeningeal neoplasia. Neurosurgery. 1997;41:1039-1049.
93. Epstein C, Lynch T, Shefner J, et al. Use of the immunotoxin N901-blocked ricin in patients with small-cell lung cancer. Int J Cancer. 1994;8:57-59.
94. Lynch TJ, Lambert JM, Coral F, et al. Immunotoxin therapy of small-cell lung cancer: a phase I study of N901-blocked ricin. J Clin Oncol. 1997;15:723-734.
95. Foss FM, Bacha P, Osann KE, Demierre MF, Bell T, Kuzel T. Biological correlates of acute hypersensitivity events with DAB(389)IL-2 (denileukin diftitox, ONTAK) in cutaneous T-cell lymphoma: decreased frequency and severity with steroid premedication. Clin Lymphoma. 2001;1:298-302.
96. Frankel AE, Fleming DR, Hall PD, et al. A phase II study of DT fusion protein denileukin diftitox in patients with fludarabine-refractory chronic lymphocytic leukemia. Clin Cancer Res. 2003;9:3555-3561.
97. Dang NH, Hagemeister FB, Pro B, et al. Phase II study of denileukin diftitox for relapsed/refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2004;22:4095-4102.
98. Kreitman RJ, Wilson WH, Bergeron K, et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med. 2001;345:241-247.
99. Kreitman RJ, Wilson WH, Robbins D, et al. Responses in refractory hairy cell leukemia to a recombinant immunotoxin. Blood. 1999;94:3340-3348.
100. Kreitman RJ, Wilson WH, White JD, et al. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol. 2000;18:1622-1636.
101. Frankel AE, Powell BL, Hall PD, Case LD, Kreitman RJ. Phase I trial of a novel diphtheria toxin/granulocyte macrophage colony-stimulating factor fusion protein (DT388GMCSF) for refractory or relapsed acute myeloid leukemia. Clin Cancer Res. 2002;8:1004-1013.
102. Pai-Scherf LH, Kreitman RJ, Pastan I. Monoclonal antibodies: basic principles. Immunotoxins and recombinant immunotoxins. In: Rosenberg SA, ed. Principles and Practice of the Biologic Therapy of Cancer. 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2000:382-395.
103. Benhar I, Reiter Y, Pai LH, Pastan I. Administration of disulfide-stabilized Fv-immunotoxins B1(dsFv)-PE38 and B3(dsFv)-PE38 by continuous infusion increases their efficacy in curing large tumor xenografts in nude mice. Int J Cancer. 1995;62:351-355.
104. Goldberg MR, Heimbrook DC, Russo P, et al. Phase I clinical study of recombinant oncotoxin TP40 in superficial bladder cancer. Clin Cancer Res. 1995;1:57-61.
105. Sampson JH, Akabani G, Archer GE, et al. Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. J Neurooncol. 2003;65:27-35.
106. Posey JA, Khazaeli MB, Bookman MA, et al. Phase I trial of the single-chain immunotoxin SGN-10 (BR96 sFv-PE40) in patients with advanced solid tumors. Clin Cancer Res. 2002;8:3092-3099.
107. Haggerty HG, Warner WA, Comereski CR, et al. BR96 sFv-PE40 immunotoxin: nonclinical safety assessment. Toxicol Pathol. 1999;27:87-94.
108. Damle B, Tay L, Comereski C, Warner W, Kaul S. Influence of immunogenicity on the pharmacokinetics of BMS-191352, a Pseudomonas exotoxin immunoconjugate, in rats and dogs. J Pharm Pharmacol. 2000;52:671-678.
109. Pai-Scherf LH, Villa J, Pearson D, et al. Hepatotoxicity in cancer patients receiving erb-38, a recombinant immunotoxin that targets the erbB2 receptor. Clin Cancer Res. 1999;5:2311-2315.
110. Rand RW, Kreitman RJ, Patronas N, Varricchio F, Pastan I, Puri RK. Intratumoral administration of a recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high grade glioma. Clin Cancer Res. 2000;6:2157-2165.
111. Weber FW, Floeth F, Asher A. Local convection enhanced delivery of IL4-Pseudomonas exotoxin (NBI-3001) for treatment of patients with recurrent malignant glioma. In: Westphal M, Tonn JC, Ram Z, eds. Local Therapies for Glioma: Present Status and Future Developments. Vienna, Austria: Springer-Verlag Wien; 2003:93-103.
112. Husain SR, Puri RK. Interleukin-13 receptor as a specific molecular target for cytotoxin therapy of human renal cell carcinoma in a xenograft model. Clin Cancer Res. 1999;5:3766s.
113. Puri RK, Leland P, Obiri NI, et al. Targeting of interleukin-13 receptor on human renal cell carcinoma cells by a recombinant chimeric protein composed of interleukin-13 and a truncated form of Pseudomonas exotoxin A (PE38QQR). Blood. 1996;87:4333-4339.
114. Kunwar S. Convection enhanced delivery of IL13-PE38QQR for treatment of recurrent malignant glioma: presentation of interim findings from ongoing phase 1 studies. In: Westphal M, Tonn JC, Ram Z, eds. Local Therapies for Glioma: Present Status and Future Developments. Vienna, Austria: Springer-Verlag Wien; 2003:105-111.
115. Chowdhury PS, Viner JL, Beers R, Pastan I. Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity. Proc Natl Acad Sci USA. 1998;95:669-674.
116. Foss FM, Saleh MN, Krueger JG, Nichols JC, Murphy JR. Diphtheria toxin fusion proteins. In: Frankel AE, ed. Clinical Applications of Immunotoxins. Berlin, Germany: Springer-Verlag; 1998:63-81.
117. Taniguchi T, Minami Y. The IL2/IL-2 receptor system: a current overview. Cell. 1993;73:5-8.
118. Kodaka T, Uchiyama T, Ishikawa T, et al. Interleukin-2 receptor β-chain (p70-75) expressed on leukemic cells from adult T cell leukemia patients. Jpn J Cancer Res. 1990;81:902-908.
119. Yagura H, Tamaki T, Furitsu T, et al. Demonstration of high-affinity interleukin-2 receptors on B-chronic lymphocytic leukemia cells: functional and structural characterization. Blut. 1990;60:181-186.
120. Kreitman RJ, Pastan I. Recombinant single-chain immunotoxins against T and B cell leukemias. Leuk Lymphoma. 1994;13:1-10.
121. Strauchen JA, Breakstone BA. IL-2 receptor expression in human lymphoid lesions. Am J Pathol. 1987;126:506-512.
122. Robb RJ, Greene WC, Rusk CM. Low and high affinity cellular receptors for interleukin 2. J Exp Med. 1984;160:1126-1146.
123. Bacha P, Williams DP, Waters C, Williams JM, Murphy JR, Strom TB. Interleukin 2 receptor-targeted cytotoxicity: interleukin 2 receptor-mediated action of a diphtheria toxin-related interleukin 2 fusion protein. J Exp Med. 1988;167:612-622.
124. 486IL-2) in patient with chronic lymphocytic leukaemia. Lancet. 1991;337:1124-1125.
125. 486IL-2) in hematologic malignancies expressing the IL-2 receptor. Blood. 1992;79:2547-2554.
126. 486IL-2 in hematological cancers. Cancer Res. 1993;53:3930-3934.
127. 389IL-2) in lymphomas expressing the receptor for interleukin-2. Blood. 1998;91:399-405.
128. Olsen E, Duvic M, Frankel A, et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol. 2001; 19:376-388.
129. Duvic M, Kuzel TM, Olsen E, Martin AG. Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with Denileukin Diftitox (ONTAK). Clin Lymphoma. 2002;2:222-228.
130. Railan D, Fivenson DP, Wittenberg G. Capillary leak syndrome in a patient treated with interleukin 2 fusion toxin for cutaneous T-cell lymphoma. J Am Acad Dermatol. 2000;43:323-324.
131. Duvic M. Bexarotene and DAB {389} IL-2 (Denileukin diftitox, ONTAK) in treatment of cutaneous t-cell lymphomas: algorithms. Clin Lymphoma. 2000;1:S51-S55.
132. Talpur R, Apisarnthanarax N, Ward S, Duvic M. Treatment of refractory peripheral T-cell lymphoma with denileukin diftitox (ONTAK). Leuk Lymphoma. 2002;43:121-126.
133. McGinnis KS, Shapiro M, Junkins-Hopkins JM, et al. Denileukin diftitox for the treatment of panniculitic lymphoma. Arch Dermatol. 2002;138:740-742.
134. Martin A, Gutierrez E, Muglia J, et al. A multicenter dose-escalation trial with denileukin diftitox (ONTAK, DAB(389)IL-2) in patients with severe psoriasis. J Am Acad Dermatol. 2001;45:871-881.
135. Shao RH, Tian X, Gorgun G, Urbano AG, Foss FM. Arginine butyrate increases the cytotoxicity of DAB(389)IL-2 in leukemia and lymphoma cells by upregulation of IL-2Rbeta gene. Leuk Res. 2002;26:1077-1083.
136. Gorgun G, Foss F. Immunomodulatory effects of RXR rexinoids: modulation of high-affinity IL-2R expression enhances susceptibility to denileukin diftitox. Blood. 2002;100:1399-1403.
137. Uchiyama T, Broder S, Waldmann TA. A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells, I: production of anti-Tac monoclonal antibody and distribution of Tac (+) cells. J Immunol. 1981;126:1393-1397.
138. Weissman AM, Harford JB, Svetlik PB, et al. Only high-affinity receptors for interleukin 2 mediate internalization of ligand. Proc Natl Acad Sci USA. 1986;83:1463-1466.
139. Chaudhary VK, Gallo MG, FitzGerald DJ, Pastan I. A recombinant single-chain immunotoxin composed of anti-Tac variable regions and a truncated diphtheria toxin. Proc Natl Acad Sci USA. 1990;87:9491-9494.
140. Kreitman RJ, Pastan I. Accumulation of a recombinant immunotoxin in a tumor in vivo: fewer than 1000 molecules per cell are sufficient for complete responses. Cancer Res. 1998;58:968-975.
141. Bird RE, Hardman KD, Jacobson JW, et al. Single-chain antigen-binding proteins. Science. 1988;242:423-426.
142. Huston JS, Levinson D, Mudgett-Hunter M, et al. Protein engineering of antibody binding sites: recovery of specific activity in an antidigoxin single-chain Fv analogue produced in Escherichia coli. Proc Natl Acad Sci USA. 1988;85:5879-5883.
143. Chaudhary VK, Queen C, Junghans RP, Waldmann TA, FitzGerald DJ, Pastan I. A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin. Nature. 1989;339:394-397.
144. Kobayashi H, Kao CK, Kreitman RJ, et al. Pharmacokinetics of In-111-and I-125-labeled antiTac single-chain Fv recombinant immunotoxin. J Nucl Med. 2000;41:755-762.
145. Kreitman RJ, Bailon P, Chaudhary VK, FitzGerald DJP, Pastan I. Recombinant immunotoxins containing anti-Tac(Fv) and derivatives of Pseudomonas exotoxin produce complete regression in mice of an interleukin-2 receptor-expressing human carcinoma. Blood. 1994;83:426-434.
146. Kreitman RJ, Pastan I. Targeting Pseudomonas exotoxin to hematologic malignancies. Semin Cancer Biol. 1995;6:297-306.
147. Robbins DH, Margulies I, Stetler-Stevenson M, Kreitman RJ. Hairy cell leukemia, a B-cell neoplasm which is particularly sensitive to the cytotoxic effect of anti-Tac(Fv)-PE38 (LMB-2). Clin Cancer Res. 2000;6:693-700.
148. Decker T, Hipp S, Kreitman RJ, Pastan I, Peschel C, Licht T. Sensitization of B-CLL cells to recombinant immunotoxin by immunostimulatory phosphorothioate oligonucleotides. Blood. 2002;99:1320-1326.
149. Ohno N, Kreitman RJ, Saito T, et al. Augmentation of the activity of an immunotoxin, anti-Tac(Fv)-PE40KDEL, in T cell lines infected with human T cell leukemia virus type-I. Leuk Lymphoma. 2002;43:885-888.
150. Onda M, Kreitman RJ, Vasmatzis G, Lee B, Pastan I. Reduction of the nonspecific toxicity of anti-Tac(Fv)-PE38 by mutations in the framework regions of the Fv which lower the isoelectric point. J Immunol. 1999; 163:6072-6077.
151. Onda M, Willingham M, Wang Q, et al. Inhibition of TNF alpha produced by Kupffer cells protects against the non-specific liver toxicity of immunotoxin anti-Tac(Fv)-PE38, LMB-2. J Immunol. 2000;165:7150-7156.
152. Schnell R, Vitetta E, Schindler J, et al. Clinical trials with an anti-CD25 ricin A-chain experimental and immunotoxin (RFT5-SMPT-dgA) in Hodgkin's lymphoma. Leuk Lymphoma. 1998;30:525-537.
153. Schnell R, Borchmann P, Staak JO, et al. Clinical evaluation of ricin A-chain immunotoxins in patients with Hodgkin's lymphoma. Ann Oncol. 2003;14:729-736.
154. Montagna D, Yvon E, Calcaterra V, et al. Depletion of alloreactive T cells by a specific anti-interleukin-2 receptor p55 chain immunotoxin does not impair in vitro antileukemia and antiviral activity. Blood. 1999;93:3550-3557.
155. Martin PJ, Pei J, Gooley T, et al. Evaluation of a CD25-specific immunotoxin for prevention of graft-versus-host disease after unrelated marrow transplantation. Biol Blood Marrow Transplant. 2004;10:552-560.
156. Reiter Y, Brinkmann U, Kreitman RJ, Jung S-H, Lee B, Pastan I. Stabilization of the Fv fragments in recombinant immunotoxins by disulfide bonds engineered into conserved framework regions. Biochemistry. 1994;33:5451-5459.
157. Reiter Y, Kreitman RJ, Brinkmann U, Pastan I. Cytotoxic and antitumor activity of a recombinant immunotoxin composed of disulfide-stabilized anti-Tac Fv fragment and truncated Pseudomonas exotoxin. Int J Cancer. 1994;58:142-149.
158. Kreitman RJ, Schneider WP, Queen C, et al. Mik-β1(Fv)-PE40, a recombinant immunotoxin cytotoxic toward cells bearing the β-chain of the IL-2 receptor. J Immunol. 1992;149:2810-2815.
159. Barth S, Huhn M, Wels W, Diehl V, Engert A. Construction and in vitro evaluation of RFT5(scFv)-ETA', a new recombinant single-chain immunotoxin with specific cytotoxicity toward CD25+ Hodgkin-derived cell lines. Int J Mol Med. 1998;1:249-256.
160. Barth S, Huhn M, Matthey B, et al. Recombinant anti-CD25 immunotoxin RFT5(ScFv)-ETA' demonstrates successful elimination of disseminated human Hodgkin lymphoma in SCID mice. Int J Cancer. 2000;86:718-724.
161. Matthey B, Engert A, Barth S. Recombinant immunotoxins for the treatment of Hodgkin's disease (Review). Int J Mol Med. 2000;6:509-514.
162. Ghetie M-A, May RD, Till M, et al. Evaluation of ricin A-chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy. Cancer Res. 1988;48:2610-2617.
163. Ghetie M-A, Richardson J, Tucker T, Jones D, Uhr JW, Vitetta ES. Antitumor activity of Fab' and IgG-anti-CD22 immunotoxins in disseminated human B lymphoma grown in mice with severe combined immunodeficiency disease: effect on tumor cells in extranodal sites. Cancer Res. 1991;51:5876-5880.
164. Bregni M, Siena S, Formosa A, et al. B-cell restricted saporin immunotoxins: activity against B-cell lines and chronic lymphocytic
165. Senderowicz AM, Vitetta E, Headlee D, et al. Complete sustained response of a refractory, post-transplantation, large B-cell lymphoma to an anti-CD22 immunotoxin. Ann Intern Med. 1997;126:882-885.
166. Smallshaw JE, Ghetie V, Rizo J, et al. Genetic engineering of an immunotoxin to eliminate pulmonary vascular leak in mice. Nat Biotechnol. 2003;21:387-391.
167. Kreitman RJ. Taming ricin toxin. Nat Biotechnol. 2003;21:372-374.
168. Kreitman RJ, Hansen HJ, Jones AL, FitzGerald DJ, Goldenberg DM, Pastan I. Pseudomonas exotoxin-based immunotoxins containing the antibody LL2 or LL2-Fab'induce regression of subcutaneous human B-cell lymphoma in mice. Cancer Res. 1993;53:819-825.
169. Mansfield E, Chiron MF, Amlot P, Pastan I, FitzGerald DJ. Recombinant RFB4 single-chain immunotoxin that is cytotoxic towards CD22-positive cells. Biochem Soc Trans. 1997;25:709-714.
170. Mansfield E, Amlot P, Pastan I, FitzGerald DJ. Recombinant RFB4 immunotoxins exhibit potent cytotoxic activity for CD22-bearing cells and tumors. Blood. 1997;90:2020-2026.
171. Kreitman RJ, Wang QC, FitzGerald DJ, Pastan I. Complete regression of human B-cell lymphoma xenografts in mice treated with recombinant anti-CD22 immunotoxin RFB4(dsFv)-PE38 at doses tolerated by cynomolgus monkeys. Int J Cancer. 1999;81:148-155.
172. Kreitman RJ, Margulies I, Stetler-Stevenson M, Wang QC, FitzGerald DJ, Pastan I. Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) towards fresh malignant cells from patients with B-cell leukemias. Clin Cancer Res. 2000;6:1476-1487.
173. Salvatore G, Beers R, Margulies I, Kreitman RJ, Pastan I. Improved cytotoxic activity towards cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display. Clin Cancer Res. 2002;8:995-1002.
174. Kreitman RJ, Squires DR, Stetler-Stevenson M, et al. Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies. J Clin Oncol. 2005;23:6719-6729.
175. Matutes E, Wotherspoon A, Brito-Babapulle V, Catovsky D. The natural history and clinico-pathological features of the variant form of hairy cell leukemia. Leukemia. 2001;15:184-186.
176. Tallman MS, Hakimian D, Kopecky KJ, et al. Minimal residual disease in patients with hairy cell leukemia in complete remission treated with 2-chlorodeoxyadenosine or 2-deoxycoformycin and prediction of early relapse. Clin Cancer Res. 1999;5:1665-1670.
177. Kreitman RJ, Pastan I. Recombinant toxins containing human granulocyte-macrophage colony-stimulating factor and either Pseudomonas exotoxin or diphtheria toxin kill gastrointestinal cancer and leukemia cells. Blood. 1997;90:252-259.
178. Hall PD, Virella G, Willoughby T, Atchley DH, Kreitman RJ, Frankel AE. Antibody response to DT-GM, a novel fusion toxin consisting of a truncated diphtheria toxin (DT) linked to human granulocyte-macrophage colony stimulating factor (GM), during a phase I trial of patients with relapsed or refractory acute myeloid leukemia. Clin Immunol. 2001;100:191-197.
179. Szatrowski TP, Dodge RK, Reynolds C, et al. Lineage specific treatment of adult patients with acute lymphoblastic leukemia in first remission with anti-B4-blocked ricin or high-dose cytarabine: Cancer and Leukemia Group B Study 9311. Cancer. 2003;97:1471-1480.
180. Grossbard ML, Gribben JG, Freedman AS, et al. Adjuvant immunotoxin therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with B-cell non-Hodgkin's lymphoma. Blood. 1993;81:2263-2271.
181. Scadden DT, Schenkein DP, Bernstein Z, et al. Immunotoxin combined with chemotherapy for patients with AIDS-related non-Hodgkin's lymphoma. Cancer. 1998;83:2580-2587.
182. Grossbard ML, Multani PS, Freedman AS, et al. Phase II study of adjuvant therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with relapsed B-cell non-Hodgkin's lymphoma. Clin Cancer Res. 1999;5:2392-2398.
183. Longo DL, Duffey PL, Gribben JG, et al. Combination chemotherapy followed by an immunotoxin (anti-B4-blocked ricin) in patients with indolent lymphoma: results of a phase II study. Cancer J. 2000;6:146-150.
184. Herrera L, Yarbrough S, Ghetie V, Aquino DB, Vitetta ES. Treatment of SCID/human B cell precursor ALL with anti-CD19 and anti-CD22 immunotoxins. Leukemia. 2003;17:334-338.
185. Messmann RA, Vitetta ES, Headlee D, et al. A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma. Clin Cancer Res. 2000;6:1302-1313.
186. Schnell R, Staak O, Borchmann P, et al. Phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4.dgA) in patients with refractory CD30+ Hodgkin's and non-Hodgkin's lymphoma. Clin Cancer Res. 2002;8:1779-1786.
187. Hansen HP, Matthey B, Barth S, et al. Inhibition of metalloproteinases enhances the internalization of anti-CD30 antibody Ki-3 and the cytotoxic activity of Ki-3 immunotoxin. Int J Cancer. 2002;98:210-215.
188. Klimka A, Barth S, Matthey B, et al. An anti-CD30 single-chain Fv selected by phage display and fused to Pseudomonas exotoxin A (Ki-4(scFv)-ETA') is a potent immunotoxin against a Hodgkin-derived cell line. Br J Cancer. 1999;80:1214-1222.
189. Barth S, Huhn M, Matthey B, et al. Ki-4(scFv)-ETA', a new recombinant anti-CD30 immunotoxin with highly specific cytotoxic activity against disseminated Hodgkin tumors in SCID mice. Blood. 2000;95:3909-3914.
190. Rozemuller H, Chowdhury PS, Pastan I, Kreitman RJ. Isolation of new anti-CD30 scFvs from DNA-immunized mice by phage display and biologic activity of recombinant immunotoxins produced by fusion with truncated Pseudomonas exotoxin. Int J Cancer. 2001;92:861-870.
191. Nagata S, Onda M, Numata Y, et al. Novel anti-CD30 recombinant immunotoxins containing disulfide-stabilized Fv fragments. Clin Cancer Res. 2002;8:2345-2355.
192. Alexander RL, Kucera GL, Klein B, Frankel AE. In vitro interleukin-3 binding to leukemia cells predicts cytotoxicity of a diphtheria toxin/ IL-3 fusion protein. Bioconjug Chem. 2000;11:564-568.
193. Frankel A, McCubrey J, Miller MS, et al. Diphtheria toxin fused to human interleukin-3 is toxic to blasts from patients with acute phase chronic myeloid leukemia. Leukemia. 2000;14:576-585.
194. Alexander RL, Ramage J, Kucera GL, Caligiuri MA, Frankel AE. High affinity interleukin-3 receptor expression on blasts from patients with acute myelogenous leukemia correlates with cytotoxicity of a diphtheria toxin/IL-3 fusion protein. Leuk Res. 2001; 25:875-881.
195. Feuring-Buske M, Frankel AE, Alexander RL, Gerhard B, Hogge DE. A diphtheria toxin-interleukin 3 fusion protein is cytotoxic to primitive acute myeloid leukemia progenitors but spares normal progenitors. Cancer Res. 2002;62:1730-1736.
196. Black JH, McCubrey JA, Willingham MC, Ramage J, Hogge DE, Frankel AE. Diphtheria toxin-interleukin-3 fusion protein (DT(388)IL3) prolongs disease-free survival of leukemic immunocompromised mice. Leukemia. 2003;17:155-159.
197. Urieto JO, Liu T, Black JH, et al. Expression and purification of the recombinant diphtheria fusion toxin DT388IL3 for phase I clinical trials. Protein Expr Purif. 2004;33:123-133.
198. Flavell DJ, Boehm DA, Noss A, Warnes SL, Flavell SU. Therapy of human T-cell acute lymphoblastic leukaemia with a combination of anti-CD7 and anti-CD38-SAPORIN immunotoxins is significantly better than therapy with each individual immunotoxin. Br J Cancer. 2001;84:571-578.
199. Mehta K, Ocanas L, Malavasi F, Marks JW, Rosenblum MG. Retinoic acid-induced CD38 antigen as a target for immunotoxin-mediated killing of leukemia cells. Mol Cancer Ther. 2004;3: 345-352.
200. Pcipp M, Kupers H, Saul D, et al. A recombinant CD7-specific single-chain immunotoxin is a potent inducer of apoptosis in acute leukemic T cells. Cancer Res. 2002;62:2848-2855.
201. Polito L, Bolognesi A, Tazzari PL, et al. The conjugate Rituximab/ saporin-S6 completely inhibits clonogenic growth of CD20-expressing cells and produces a synergistic toxic effect with Fludarabine. Leukemia. 2004;18:1215-1222.
202. Zhong RK, van De Winkel JG, Thepen T, Schultz LD, Ball ED. Cytotoxicity of anti-cd64-ricin a chain immunotoxin against human acute myeloid leukemia cells in vitro and in SCID mice. J Hematother Stem Cell Res. 2001;10:95-105.
203. Tur MK, Huhn M, Thepen T, et al. Recombinant CD64-specific single chain immunotoxin exhibits specific cytotoxicity against acute myeloid leukemia cells. Cancer Res. 2003;63:8414-8419.
204. Otten HG, deGast GC, Vooijs WC. Preclinical evaluation of anti-CD86 immunotoxin in rhesus monkeys: analysis of systemic toxicity, pharmacokinetics, and effect on primary t-cell responses. Cancer Immunol Immunother. 2003;52:569-575.
205. Shin YK, Choi YL, Choi EY, et al. Targeted cytotoxic effect of anti-JL1 immunotoxin against a human leukemic cell line and its clinical implications, Cancer Immunol Immunother. 2003;52:506-512.
206. Pistillo MP, Tazzari PL, Palmisano GL, et al. CTLA-4 is not restricted to the lymphoid cell lineage and can function as a target molecule for apoptosis induction of leukemic cells. Blood. 2003;101:202-209.
207. FitzGerald DJ, Padmanabhan R, Pastan I, Willingham MC. Adenovirus-induced release of epidermal growth factor and pseudomonas toxin into the cytosol of KB cells during receptor-mediated endocytosis. Cell. 1983;32:607-617.
208. Chaudhary VK, FitzGerald DJ, Adhya S, Pastan I. Activity of a recombinant fusion protein between transforming growth factor type α and Pseudomonas toxin. Proc Natl Acad Sci USA. 1987;84:4538-4542.
209. Siegall CB, Xu Y-h, Chaudhary VK, Adhya S, FitzGerald D, Pastan I. Cytotoxic activities of a fusion protein comprised of TGFα and Pseudomonas exotoxin. FASEB J. 1989;3:2647-2652.
210. Kreitman RJ, Siegall CB, Chaudhary VK, FitzGerald DJ, Pastan I. Properties of chimeric toxins with two recognition domains: interleukin 6 and transforming growth factor α at different locations in Pseudomonas exotoxin. Bioconjug Chem. 1992;3:63-68.
211. Pai LH, Gallo MG, FitzGerald DJ, Pastan I. Antitumor activity of a transforming growth factor α-Pseudomonas exotoxin fusion protein (TGF-α-PE40). Cancer Res. 1991;51:2808-2812.
212. Shaw JP, Degen D, Nichols JC, Bacha P, Von Hoff DD. Cytotoxicity of an epidermal growth factor receptor targeted fusion toxin for primary and cultured human tumor cells. Proc Am Assoc Cancer Res. 1993;34:2043.
213. Liu TF, Willingham MC, Tatter SB, et al. Diphtheria toxin-epidermal growth factor fusion protein and Pseudomonas exotoxin-interleukin 13 fusion protein exert synergistic toxicity against human glioblastoma multiforme cells. Bioconjug Chem. 2003;14:1107-1114.
214. Mishra G, Liu TF, Frankel AE. Recombinant toxin DAB389EGF is cytotoxic to human pancreatic cancer cells. Expert Opin Biol Ther. 2003:3:1173-1180.
215. Bruell D, Stocker M, Huhn M, et al. The recombinant anti-EGF receptor immunotoxin 425(scFv)-ETA' suppresses growth of a highly metastatic pancreatic carcinoma cell line. Int J Oncol. 2003;23:1179-1186.
216. Lorimer IAJ, Wikstrand CJ, Batra SK, Bigner DD, Pastan I. Immunotoxins that target an oncogenic mutant epidermal growth factor receptor expressed in human tumors. Clin Cancer Res. 1995;1:859-864.
217. Lorimer IA, Keppler-Hafkemeyer A, Beers RA, Pegram CN, Bigner DD, Pastan I. Recombinant immunotoxins specific for a mutant epidermal growth factor receptor: targeting with a single chain antibody variable domain isolated by phage display. Proc Natl Acad Sci USA. 1996;93:14815-14820.
218. Fu YM, Mesri EA, Yu ZX, Kreitman RJ, Pastan I, Epstein SE. Cytotoxic effects of vascular smooth muscle cells of the chimeric toxin, heparin binding TGF α-Pseudomonas exotoxin. Cardiovasc Res. 1993; 27:1691-1697.
219. Mesri EA, Kreitman RJ, Fu YM, Epstein SE, Pastan I. Heparin-binding transforming growth factor α-Pseudomonas exotoxin A. J Biol Chem. 1993;268:4853-4862.
220. Mesri EA, Ono M, Kreitman RJ, Klagsbrun M, Pastan I. The heparin-binding domain of heparin-binding EGF-like growth factor can target Pseudomonas exotoxin to kill cells exclusively through heparan sulfate proteoglycans. J Cell Sci. 1994;107:2599-2608.
221. Pastan I, Lovelace ET, Gallo MG, Rutherford AV, Magnani JL, Willingham MC. Characterization of monoclonal antibodies B1 and B3 that react with mucinous adenocarcinomas. Cancer Res. 1991;51:3781-3787.
222. Pai LH, Kreitman RJ, Pastan I. Immunotoxin therapy. In: Devita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 6th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2000:382-395.
223. Pai LH, Batra JK, FitzGerald DJ, Willingham MC, Pastan I. Antitumor effects of B3-PE and B3-LysPE40 in a nude mouse model of human breast cancer and the evaluation of B3-PE toxicity in monkeys. Cancer Res. 1992;52:3189-3193.
224. Pai LH, Batra JK, FitzGerald DJ, Willingham MC, Pastan I. Antitumor activities of immunotoxins made of monoclonal antibody B3 and various forms of Pseudomonas exotoxin. Proc Natl Acad Sci USA. 1991;88:3358-3362.
225. Y damage human endothelial cells in an antibody-specific mode: relevance to vascular leak syndrome. Clin Cancer Res. 1995;1:1589-1594.
226. Brinkmann U, Pai LH, FitzGerald DJ, Willingham M, Pastan I. B3(Fv)-PE38KDEL, a single-chain immunotoxin that causes complete regression of a human carcinoma in mice. Proc Natl Acad Sci USA. 1991;88:8616-8620.
227. Harari D, Yarden Y. Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene. 2000;19:6102-6114.
228. Wels W, Beerli R, Hellmann P, et al. EGF receptor and p185 (erB-2)-specific single-chain antibody toxins differ in their cell-killing activity on tumor cells expressing both receptor proteins. Int J Cancer. 1995;60:137-144.
229. Schmidt M, Hynes NE, Groner B, Wels W. A bivalent single-chain antibody-toxin specific for ErbB-2 and the EGF receptor. Int J Cancer. 1996;65:538-546.
230. Batra JK, Kasprzyk PG, Bird RE, Pastan I, King CR. Recombinant anti-erbB2 immunotoxins containing Pseudomonas exotoxin. Proc Natl Acad Sci USA. 1992;89:5867-5871.
231. Shinohara H, Morita S, Kawai M, et al. Expression of HER2 in human gastric cancer cells directly correlates with antitumor activity of a recombinant disulfide-stabilized anti-HER2 immunotoxin. J Surg Res. 2002;102:169-177.
232. Azemar M, Schmidt M, Arlt F, et al. Recombinant antibody toxins specific for ErbB2 and EGF receptor inhibit the in vitro growth of human head and neck cancer cells and cause rapid tumor regression in vivo. Int J Cancer. 2000;86:269-275.
233. Azemar M, Djahansouzi S, Jager E, et al. Regression of cutaneous tumor lesions in patients intratumorally injected with a recombinant single-chain antibody-toxin targeted to ErbB2/HER2. Breast Cancer Res Treat. 2003;82:155-164.
234. Husain SR, Gill P, Kreitman RJ, Pastan I, Puri RK. Interleukin-4 receptor expression on AIDS-associated Kaposi's sarcoma cells and their targeting by a chimeric protein comprised of circularly permuted IL-4 and Pseudomonas exotoxin. Mol Med. 1997;3:327-338.
235. Debinski W, Puri RK, Kreitman RJ, Pastan I. A wide range of human cancers express interleukin 4 (IL4) receptors that can be targeted with chimeric toxin composed of IL4 and Pseudomonas exotoxin. J Biol Chem. 1993;268:14065-14070.
236. Kreitman RJ, Puri RK, Leland P, Lee B, Pastan I. Site-specific conjugation to interleukin 4 containing mutated cysteine residues produces interleukin 4-toxin conjugates with improved binding and activity. Biochemistry. 1994;33:11637-11644.
237. Kreitman RJ. Circularly permuted interleukin 4 retains proliferative and binding activity. Cytokine. 1995;7:311-318.
238. Kreitman RJ, Puri RK, Pastan I. Increased antitumor activity of a circularly permuted interleukin 4-toxin in mice with interleukin 4 receptor-bearing human carcinoma. Cancer Res. 1995;55:3357-3363.
239. Kreitman RJ, Puri RK, Pastan I. A circularly permuted recombinant interleukin 4 toxin with increased activity. Proc Natl Acad Sci USA. 1994;91:6889-6893.
240. Husain SR, Behari N, Kreitman RJ, Pastan I, Puri RK. Complete regression of established human glioblastoma tumor xenografts by interleukin-4 toxin therapy. Cancer Res. 1998;58:3649-3653.
241. Puri RK, Hoon DS, Leland P, et al. Preclinical development of a recombinant toxin containing circularly permuted interleukin 4 and truncated Pseudomonas exotoxin for therapy of malignant astrocytoma. Cancer Res. 1996;56:5631-5637.
242. Obiri NI, Debinski W, Leonard WJ, Puri RK. Receptor for interleukin 13. Interaction with interleukin 4 by a mechanism that does not involve the common gamma chain shared by receptors for interleukins 2, 4, 7, 9, and 15. J Biol Chem. 1995;270:8797-8804.
243. Obiri NI, Leland P, Murata T, Debinski W, Puri RK. The IL-13 receptor structure differs on various cell types and may share more than one component with IL-4 receptor. J Immunol. 1997;158:756-764.
244. Weaver M, Laske DW. Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas. J Neurooncol. 2003;65:3-13.
245. Hagihara N, Walbridge S, Olson AW, Oldfield EH, Youle RJ. Vascular protection by chloroquine during brain tumor therapy with Tf-CRM107. Cancer Res. 2000;60:230-234.
246. Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci USA. 1996;93:136-140.
247. Chowdhury PS, Chang K, Pastan I. Isolation of anti-mesothelin antibodies from a phage display library. Mol Immunol. 1997;34:9-20.
248. Hassan R, Benbrook DM, Lightfoot SA, et al. SS1(dsFv)-PE38, a recombinant anti-mesothelin immunotoxin targets human gynecologic tumors overexpressing mesothelin. Proc Am Soc Clin Oncol. 2000;19:383a.
249. Hassan R, Lerner MR, Benbrook D, et al. Antitumor activity of SS(dsFv)PE38 and SS1(dsFv)PE38, recombinant antimesothelin immunotoxins against human gynecologic cancers grown in organotypic culture in vitro. Clin Cancer Res. 2002;8:3520-3526.
250. Li Q, Verschraegen CF, Mendoza J, Hassan R. Cytotoxic activity of the recombinant anti-mesothelin immunotoxin, SS1(dsFv)PE38, towards tumor cell lines established from ascites of patients with peritoneal mesotheliomas. Anticancer Res. 2004;24:1327-1335.
251. Fan D, Yano S, Shinohara H, et al. Targeted therapy against human lung cancer in nude mice by high-affinity recombinant antimesothelin single-chain Fv immunotoxin. Mol Cancer Ther. 2002;1:595-600.
252. Bera TK, Williams-Gould J, Beers R, Chowdhury P, Pastan I. Bivalent disulfide-stabilized fragment variable immunotoxin directed against mesotheliomas and ovarian cancer. Mol Cancer Ther. 2001;1:79-84.
253. Lynch TJ. Immunotoxin therapy of small-cell lung cancer. N901-blocked ricin for relapsed small-cell lung cancer. Chest. 1993;103:436s-439s.
254. Fidias P, Jr, Grossbard M, Jr, Lynch TJ, Jr. A phase II study of the immunotoxin N901-blocked ricin in small-cell lung cancer. Clin Lung Cancer. 2002;3:219-222.
255. Lanza F, Castoldi GL, Castagnari B, et al. Expression and functional role of urokinase-type plasminogen activator receptor in normal and acute leukaemic cells. Br J Haematol. 1998; 103:110-123.
256. Plesner T, Ralfkiaer E, Wittrup M, et al. Expression of the receptor for urokinase-type plasminogen activator in normal and neoplastic blood cells and hematopoietic tissue. Am J Clin Pathol. 1994;102:835-841.
257. Taniguchi T, Kakkar AK, Tuddenham EGD, Williamson RCN, Lemoine NR. Enhanced expression of urokinase receptor induced through the tissue factor-factor VHa pathway in human pancreatic cancer. Cancer Res. 1998;58:4461-4467.
258. Sier CFM, Stephens R, Bizik J, et al. The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients. Cancer Res. 1998;58:1843-1849.
259. Rajagopal V, Kreitman RJ. Recombinant toxins which bind to the urokinase receptor are cytotoxic without requiring binding to the α2 macroglobulin receptor. J Biol Chem. 2000;275:7566-7573.
260. Ramage JG, Vallera DA, Black JH, Aplan PD, Kees UR, Frankel AE. The diphtheria toxin/urokinase fusion protein (DTAT) is selectively toxic to CD87 expressing leukemic cells. Leuk Res. 2003;27:79-84.
261. Frankel AE, Beran M, Hogge DE, et al. Malignant progenitors from patients with CD87+ acute myelogenous leukemia are sensitive to a diphtheria toxin-urokinase fusion protein. Exp Hematol. 2002;30:1316-1323.
262. Vallera DA, Li C, Jin N, Panoskaltsis-Mortari A, Hall WA. Targeting urokinase-type plasminogen activator receptor on human glioblastoma tumors with diphtheria toxin fusion protein DTAT. J Natl Cancer Inst. 2002;94:597-606.
263. Rustamzadeh E, Li C, Doumbia S, Hall WA, Vallera DA. Targeting the over-expressed urokinase-type plasminogen activator receptor on glioblastoma multiforme. J Neurooncol. 2003;65:63-75.
264. Todhunter DA, Hall WA, Rustamzadeh E, Shu Y, Doumbia SO, Vallera DA. A bispecific immunotoxin (DTAT13) targeting human IL-13 receptor (IL-13R) and urokinase-type plasminogen activator receptor (uPAR) in a mouse xenograft model. Protein Eng Des Sel. 2004;17:157-164.
265. Rosenblum MG, Murray JL, Cheung L, Rifkin R, Salmon S, Bartholomew R. A specific and potent immunotoxin composed of antibody ZME-018 and the plant toxin gelonin. Mol Biother. 1991;3:6-13.
266. Rosenblum MG, 3rd, Cheung LH, 3rd, Liu Y, 3rd, Marks JW, 3rd. Design, expression, purification, and characterization, in vitro and in vivo, of an antimelanoma single-chain Fv antibody fused to the toxin gelonin. Cancer Res. 2003;63:3995-4002.
267. Chan MC, Murphy RM. Kinetics of cellular trafficking and cytotoxicity of 9.2.27-gelonin immunotoxins targeted against the high-molecular-weight melanoma-associated antigen. Cancer Immunol Immunother. 1999;47:321-329.
268. Hjortland GO, Garman-Vik SS, Juell S, et al. Immunotoxin treatment targeted to the high-molecular-weight melanoma-associated antigen prolonging the survival of immunodeficient rats with invasive intracranial human glioblastoma multiforme. J Neurosurg. 2004;100:320-327.
269. Fracasso G, Bellisola G, Cingarlini S, et al. Anti-tumor effects of toxins targeted to the prostate specific membrane antigen. Prostate. 2002;53:9-23.
270. Huang X, Bennett M, Thorpe PE. Anti-tumor effects and lack of side effects in mice of an immunotoxin directed against human and mouse prostate-specific membrane antigen. Prostate. 2004;61:1-11.
271. Onda M, Wang QC, Guo HF, Cheung NK, Pastan I. In vitro and in vivo cytotoxic activities of recombinant immunotoxin 8H9(Fv)-PE38 against breast cancer, osteosarcoma, and neuroblastoma. Cancer Res. 2004;64:1419-1424.
272. Thomas PB, Delatte SJ, Sutphin A, Frankel AE, Tagge EP. Effective targeted cytotoxicity of neuroblastoma cells. J Pediatr Surg. 2002;37:539-544.
273. Di Paolo C, Willuda J, Kubetzko S, et al. A recombinant immunotoxin derived from a humanized epithelial cell adhesion molecule-specific single-chain antibody fragment has potent and selective antitumor activity. Clin Cancer Res. 2003;9:2837-2848.
274. Jin N, Chen W, Blazar BR, Ramakrishnan S, Vallera DA. Gene therapy of murine solid tumors with T cells transduced with a retroviral vascular endothelial growth factor - immunotoxin target gene. Hum Gene Ther. 2002;13:497-508.
275. Reddy KR. Development and pharmacokinetics and pharmacodynamics of pegylated interferon alfa-2a (40 kD). Semin Liver Dis. 2004;24:33-38.
276. Graham ML. Pegaspargase: a review of clinical studies. Adv Drug Deliv Rev. 2003;55:1293-1302.
277. Onda M, Vincent JJ, Lee B, Pastan I. Mutants of immunotoxin anti-Tac(dsFv)-PE38 with variable number of lysine residues as candidates for site-specific chemical modification, I: properties of mutant molecules. Bioconjug Chem. 2003; 14:480-487.
278. Tsutsumi Y, Onda M, Nagata S, Lee B, Kreitman RJ, Pastan I. Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity. Proc Natl Acad Sci USA. 2000;97:8548-8553.
279. Roscoe DM, Pai LH, Pastan I. Identification of epitopes on a mutant form of Pseudomonas exotoxin using serum from humans treated with Pseudomonas exotoxin containing immunotoxins. Eur J Immunol. 1997;27:1459-1468.
280. Roscoe DM, Jung SH, Benhar I, Pai L, Lee BK, Pastan I. Primate antibody response to immunotoxin: serological and computer-aided analysis of epitopes on a truncated form of Pseudomonas exotoxin. Infect Immun. 1994;62:5055-5065.
281. Nagata S, Numata Y, Onda M, et al. Rapid grouping of monoclonal antibodies based on their topographical epitopes by a label-free competitive immunoassay. J Immunol Methods. 2004;292:141-155.
282. Pai LH, FitzGerald DJ, Tepper M, Schacter B, Spitalny G, Pastan I. Inhibition of antibody response to Pseudomonas exotoxin and an immunotoxin containing Pseudomonas exotoxin by 15-deoxyspergualin in mice. Cancer Res. 1990;50:7750-7753.
283. Siegall CB, Haggerty HG, Warner GL, et al. Prevention of immunotoxin-induced immunogenicity by coadministration with CTLA4Ig enhances antitumor efficacy. J Immunol. 1997;159:5168-5173.
284. Gelber EE, Vitetta ES. Effect of immunosuppressive agents on the immunogenicity and efficacy of an immunotoxin in mice. Clin Cancer Res. 1998;4:1297-1304.
285. Hassan R, Williams-Gould J, Watson T, Pai-Scherf L, Pastan I. Pretreatment with rituximab does not inhibit the human immune response against the immunogenic protein LMB-1. Clin Cancer Res. 2004;10:16-18.
286. Baluna R, Rizo J, Gordon BE, Ghetie V, Vitetta ES. Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome. Proc Natl Acad Sci USA. 1999;96:3957-3962.
287. Baluna R, Coleman E, Jones C, Ghetie V, Vitetta ES. The effect of a monoclonal antibody coupled to ricin A chain-derived peptides on endothelial cells in vitro: insights into toxin-mediated vascular damage. Exp Cell Res. 2000;258:417-424.
288. Onda M, Nagata S, Tsutsumi Y, et al. Lowering the isoelectric point of the Fv portion of recombinant immunotoxins leads to decreased nonspecific animal toxicity without affecting antitumor activity. Cancer Res. 2001;61:5070-5077.
289. Grossbard W, Lambert JM, Goldmacher VS, et al. Anti-B4-blocked ricin: a phase I trial of 7-day continuous infusion in patients with B-cell neoplasms. J Clin Oncol. 1993;11:726-737.
290. Grossbard ML, Fidias P, Kinsella J, et al. Anti-B4-blocked ricin: a phase II trial of 7 day continuous infusion in patients with multiple myeloma. Br J Haematol. 1998;102:509-515.